Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2018

Open Access 01-12-2018 | Research article

Thyroid hormones and breast cancer association according to menopausal status and body mass index

Authors: Carolina Ortega-Olvera, Alfredo Ulloa-Aguirre, Angélica Ángeles-Llerenas, Fernando Enrique Mainero-Ratchelous, Claudia Elena González-Acevedo, Ma. de Lourdes Hernández-Blanco, Elad Ziv, Larissa Avilés-Santa, Edelmiro Pérez-Rodríguez, Gabriela Torres-Mejía

Published in: Breast Cancer Research | Issue 1/2018

Login to get access

Abstract

Background

Thyroxine (T4) has been positively associated with tumor cell proliferation, while the effect of triiodothyronine (T3) on cell proliferation has not been well-established because it differs according to the type of cell line used. In Mexico, it has been reported that 14.5% of adult women have some type of thyroid dysfunction and abnormalities in thyroid function tests have been observed in a variety of non-thyroidal illnesses, including breast cancer (BC). These abnormalities might change with body mass index (BMI) because thyroid hormones are involved in the regulation of various metabolic pathways and probably by menopausal status because obesity has been negatively associated with BC in premenopausal women and has been positively associated with BC in postmenopausal women.

Methods

To assess the association between serum thyroid hormone concentration (T4 and T3) and BC and the influence of obesity as an effect modifier of this relationship in premenopausal and postmenopausal women, we measured serum thyroid hormone and thyroid antibody levels in 682 patients with incident breast cancer (cases) and 731 controls, who participated in a population-based case-control study performed from 2004 to 2007 in three states of Mexico. We tested the association of total T4 (TT4) and total T3 (TT3) stratifying by menopausal status and body mass index (BMI), and adjusted for other health and demographic risk factors using logistic regressions models.

Results

Higher serum total T4 (TT4) concentrations were associated with BC in both premenopausal (odds ratio (OR) per standard deviation = 5.98, 95% CI 3.01–11.90) and postmenopausal women (OR per standard deviation = 2.81, 95% CI 2.17–3.65). In premenopausal women, the effect of TT4 decreased as BMI increased while the opposite was observed in postmenopausal women. The significance of the effect modification was marginal (p = 0.059) in postmenopausal women and was not significant in premenopausal women (p = 0.22). Lower TT3 concentrations were associated with BC in both premenopausal and postmenopausal women and no effect modification was observed.

Conclusions

There is a strong association between BC and serum concentrations of TT3 and TT4; this needs to be further investigated to understand why it happens and how important it is to consider these alterations in treatment.
Appendix
Available only for authorised users
Literature
1.
Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson UB, Malm J, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer. 2012;131:2126–33.CrossRefPubMed
2.
Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J. Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res. 2010;12:R33.CrossRefPubMedPubMedCentral
3.
Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol. 2016;12:111–21.CrossRefPubMed
4.
Meng R, Tang HY, Westfall J, London D, Cao JH, Mousa SA, et al. Crosstalk between integrin alphavbeta3 and estrogen receptor-alpha is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One. 2011;6:e27547.CrossRefPubMedPubMedCentral
5.
Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, et al. L-thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol. 2009;296:C980–91.CrossRefPubMed
6.
Nogueira CR, Brentani MM. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996;59:271–9.CrossRefPubMed
7.
Cestari SH, Figueiredo NB, Conde SJ, Clara S, Katayama ML, Padovani CR, et al. Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol. 2009;53:859–64.CrossRefPubMed
8.
Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008;109:57–66.CrossRefPubMed
9.
10.
11.
12.
13.
14.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
15.
Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16:36–46.CrossRefPubMed
16.
Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti IA. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7:e51446.CrossRefPubMedPubMedCentral
17.
Feng YH. The association between obesity and gynecological cancer. Gynecology and Minimally Invasive Therapy. 2015;4:102–5.
18.
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67:378–97.
19.
Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.CrossRefPubMedPubMedCentral
20.
Harvie M, Hooper L, Howell A. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4:157–73.CrossRefPubMed
21.
Palmer JR, Adams-Campbell LL, Boggs DA, Wise LA, Rosenberg L. A prospective study of body size and breast cancer in black women. Cancer Epidemiol Biomarkers Prev. 2007;16:1795–802.CrossRefPubMed
22.
Slattery ML, Sweeney C, Edwards S, Herrick J, Baumgartner K, Wolff R, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2007;102:85–101.CrossRefPubMed
23.
Van Den Brandt PA, Spiegelman D, Yaun S-S, Adami H-O, Beeson L, Folsom AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514–27.CrossRefPubMed
24.
Berstad P, Coates RJ, Bernstein L, Folger SG, Malone KE, Marchbanks PA, et al. A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19:1532–44.
25.
Ng EH, Gao F, Ji CY, Ho GH, Soo KC. Risk factors for breast carcinoma in Singaporean Chinese women: the role of central obesity. Cancer. 1997;80:725–31.CrossRefPubMed
26.
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, et al. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010;172:682–90.CrossRefPubMedPubMedCentral
27.
Harris H, Willett W, Terry K, Michels K. Body fat distribution and risk of premenopausal breast cancer in the Nurses’ Health Study II. J Natl Cancer Inst. 2011;103:273–8.CrossRefPubMed
28.
La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist. 2011;16:726–9.CrossRefPubMedPubMedCentral
29.
World Cancer Research Fund/American Institute for Cancer Research: Continuous update project report: diet, nutrition, physical activity and breast cancer; 2017.
30.
Chow LWC, Lui KL, Chan JCY, Chan TC, Ho PK, Lee WY, et al. Association between body mass index and risk of formation of breast cancer in Chinese women. Asian J Surg. 2005;28:179–84.CrossRefPubMed
31.
Guo Y, Warren Andersen S, Shu XO, Michailidou K, Bolla MK, Wang Q, et al. Genetically predicted body mass index and breast cancer risk: Mendelian randomization analyses of data from 145,000 women of European descent. PLoS Med. 2016;13:e1002105.CrossRefPubMedPubMedCentral
32.
33.
Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand. 2005;184:285–93.CrossRefPubMed
34.
Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327–32.CrossRefPubMed
35.
36.
Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005;90:4019–24.CrossRefPubMed
37.
Makepeace AE, Bremner AP, O'Leary P, Leedman PJ, Feddema P, Michelangeli V, et al. Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and nonsmokers. Clin Endocrinol. 2008;69:648–52.CrossRef
38.
Guan B, Chen Y, Yang J, Yang W, Wang C. Effect of bariatric surgery on thyroid function in obese patients: a systematic review and meta-analysis. Obes Surg. 2017;27:3292–305.CrossRefPubMed
39.
Nam JS, Cho M, Park JS, Ahn CW, Cha BS, Lee EJ, et al. Triiodothyronine level predicts visceral obesity and atherosclerosis in euthyroid, overweight and obese subjects: T3 and visceral obesity. Obes Res Clin Pract. 2010;4:e247–342.CrossRef
40.
Montoya-Morales DS, de los Angeles Tapia-Gonzalez M, Alamilla-Lugo L, Sosa-Caballero A, Munoz-Solis A, Jimenez-Sanchez M. Alterations of the thyroid function in patients with morbid obesity. Rev Med Inst Mex Seguro Soc. 2015;53(Suppl 1):S18–22.PubMed
41.
Kumar HK, Yadav RK, Prajapati J, Reddy CV, Raghunath M, Modi KD. Association between thyroid hormones, insulin resistance, and metabolic syndrome. Saudi Med J. 2009;30:907–11.PubMed
42.
Angeles-Llerenas A, Ortega-Olvera C, Perez-Rodriguez E, Esparza-Cano JP, Lazcano-Ponce E, Romieu I, et al. Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control. 2010;21:577–86.CrossRefPubMed
43.
Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, et al. European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomark Prev. 2010;19:1074–82.CrossRef
44.
Fejerman L, John EM, Huntsman S, Beckman K, Choudhry S, Perez-Stable E, et al. Genetic ancestry and risk of breast cancer among U.S. Latinas. Cancer Res. 2008;68:9723–8.CrossRefPubMedPubMedCentral
45.
Lohmann TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign: Human Kinetics Books; 1988.
46.
Osuna-Ramírez I, Hernández-Prado B, Campuzano JC, Salmerón J. Indice de masa corporal y percepción de la imagen corporal en una población adulta mexicana: la precisión del autorreporte. Salud Publica Mex. 2006;48:94–103.CrossRefPubMed
47.
Nagin DS. Analyzing developmental trajectories: a semiparametric, group-based approach. Psychol Methods. 1999;4:139–57.CrossRef
48.
Amadou A, Torres Mejia G, Fagherazzi G, Ortega C, Angeles-Llerenas A, Chajes V, et al. Anthropometry, silhouette trajectory, and risk of breast cancer in Mexican women. Am J Prev Med. 2014;46:S52–64.CrossRefPubMed
49.
Hernandez-Avila M, Romieu I, Parra S, Hernandez-Avila J, Madrigal H, Willett W. Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex. 1998;40:133–40.CrossRefPubMed
50.
Romieu I, Parra S, Hernandez JF, Madrigal H, Willett W, Hernandez M. Questionnaire assessment of antioxidants and retinol intakes in Mexican women. Arch Med Res. 1999;30:224–39.CrossRefPubMed
51.
52.
53.
Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, et al. Physical activity assessment methodology in the Five-City project. Am J Epidemiol. 1985;121:91–106.CrossRefPubMed
54.
Martinez-González M, Sánchez-Villegas A, Faulin-Fajardo J. Bioestadistica Amigable. 2da ed. España: Diaz de Santos; 2006.
55.
Hosmer D, Lemeshow S. Applied logistic regression. 2nd ed: John Wiley & Sons; 2000.
56.
Willett W. Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998.CrossRef
57.
Qu HQ, Li Q, Lu Y, Fisher-Hoch SP, McCormick JB. Translational genomic medicine: common metabolic traits and ancestral components of Mexican Americans. J Med Genet. 2012;49:544–5.CrossRefPubMed
58.
Bruning PF, Bonfrer JM, Hart AA, van Noord PA, van der Hoeven H, Collette HJ, et al. Body measurements, estrogen availability and the risk of human breast cancer: a case-control study. Int J Cancer. 1992;51:14–9.CrossRefPubMed
59.
Franceschi S, Favero A, La Vecchia C, Baron AE, Negri E, Dal Maso L, et al. Body size indices and breast cancer risk before and after menopause. Int J Cancer. 1996;67:181–6.CrossRefPubMed
60.
Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst. 1992;84:1575–82.CrossRefPubMed
61.
Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278:1407–11.CrossRefPubMed
62.
Kaaks R, Van Noord PA, Den Tonkelaar I, Peeters PH, Riboli E, Grobbee DE. Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch “DOM” cohort. Int J Cancer. 1998;76:647–51.CrossRefPubMed
63.
Lahmann PH, Lissner L, Gullberg B, Olsson H, Berglund G. A prospective study of adiposity and postmenopausal breast cancer risk: the Malmo diet and cancer study. Int J Cancer. 2003;103:246–52.CrossRefPubMed
64.
Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med. 2006;166:2395–402.CrossRefPubMed
65.
Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002;13:741–51.CrossRefPubMed
66.
Sonnenschein E, Toniolo P, Terry MB, Bruning PF, Kato I, Koenig KL, et al. Body fat distribution and obesity in pre- and postmenopausal breast cancer. Int J Epidemiol. 1999;28:1026–31.CrossRefPubMed
67.
Tehard B, Lahmann PH, Riboli E, Clavel-Chapelon F. Anthropometry, breast cancer and menopausal status: use of repeated measurements over 10 years of follow-up-results of the French E3N women's cohort study. Int J Cancer. 2004;111:264–9.CrossRefPubMed
68.
Vatten LJ, Kvinnsland S. Prospective study of height, body mass index and risk of breast cancer. Acta Oncol. 1992;31:195–200.CrossRefPubMed
69.
Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, Lund E, et al. A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomark Prev. 2004;13:1121–7.
70.
Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev. 2001;10:15–32.CrossRefPubMed
71.
Tehard B, Clavel-Chapelon F. Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. Int J Obes. 2006;30:156–63.CrossRefPubMedCentral
72.
Bouchardy C, Le MG, Hill C. Risk factors for breast cancer according to age at diagnosis in a French case-control study. J Clin Epidemiol. 1990;43:267–75.CrossRefPubMed
73.
Hu YH, Nagata C, Shimizu H, Kaneda N, Kashiki Y. Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan. Breast Cancer Res Treat. 1997;43:65–72.CrossRefPubMed
74.
London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE. Prospective study of relative weight, height, and risk of breast cancer. JAMA. 1989;262:2853–8.CrossRefPubMed
75.
Swanson CA, Brinton LA, Taylor PR, Licitra LM, Ziegler RG, Schairer C. Body size and breast cancer risk assessed in women participating in the breast cancer detection demonstration project. Am J Epidemiol. 1989;130:1133–41.CrossRefPubMed
76.
Tornberg SA, Holm LE, Carstensen JM. Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol. 1988;27:31–7.CrossRefPubMed
77.
Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer. 1989;44:23–30.CrossRefPubMed
78.
Vatten LJ, Kvinnsland S. Body mass index and risk of breast cancer. A prospective study of 23,826 Norwegian women. Int J Cancer. 1990;45:440–4.CrossRefPubMed
79.
Willett WC, Browne ML, Bain C, Lipnick RJ, Stampfer MJ, Rosner B, et al. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol. 1985;122:731–40.CrossRefPubMed
80.
Huang J, Jin L, Ji G, Xing L, Xu C, Xiong X, et al. Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine. BMC Cancer. 2013;13:334.CrossRefPubMedPubMedCentral
81.
Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association consortium studies. J Natl Cancer Inst. 2011;103:250–63.CrossRefPubMed
82.
Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology. 2004;145:3265–72.CrossRefPubMed
83.
Li H, Sun X, Miller E, Wang Q, Tao P, Liu L, et al. BMI, reproductive factors, and breast cancer molecular subtypes: a case-control study and meta-analysis. J Epidemiol. 2017;27:143–51.CrossRefPubMed
84.
Lin HY, Davis FB, Gordinier JK, Martino LJ, Davis PJ. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Phys. 1999;276:C1014–24.CrossRef
85.
Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem. 2000;275:38032–9.CrossRefPubMed
86.
Shih A, Lin HY, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry. 2001;40:2870–8.CrossRefPubMed
87.
Lin HY, Shih A, Davis FB, Davis PJ. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem J. 1999;338(Pt 2):427–32.CrossRefPubMedPubMedCentral
88.
Kawai M, Malone KE, Tang MT, Li CI. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. Cancer. 2014;120:1548–56.CrossRefPubMedPubMedCentral
89.
Quigley DA, Tahiri A, Luders T, Riis MH, Balmain A, Borresen-Dale AL, et al. Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. Oncoimmunology. 2017;6:e1356142.CrossRefPubMedPubMedCentral
90.
Angelousi A, Diamanti-Kandarakis E, Zapanti E, Nonni A, Ktenas E, Mantzou A, et al. Is there an association between thyroid function abnormalities and breast cancer? Arch Endocrinol Metab. 2017;61:54–61.CrossRefPubMed
91.
Mendel CM, Weisiger RA, Jones AL, Cavalieri RR. Thyroid hormone-binding proteins in plasma facilitate uniform distribution of thyroxine within tissues: a perfused rat liver study. Endocrinology. 1987;120:1742–9.CrossRefPubMed
92.
Utiger RD. Estrogen, thyroxine binding in serum, and thyroxine therapy. N Engl J Med. 2001;344:1784–5.CrossRefPubMed
93.
Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Manjer J. T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study. BMC Cancer. 2014;14:536.CrossRefPubMedPubMedCentral
Metadata
Title
Thyroid hormones and breast cancer association according to menopausal status and body mass index
Authors
Carolina Ortega-Olvera
Alfredo Ulloa-Aguirre
Angélica Ángeles-Llerenas
Fernando Enrique Mainero-Ratchelous
Claudia Elena González-Acevedo
Ma. de Lourdes Hernández-Blanco
Elad Ziv
Larissa Avilés-Santa
Edelmiro Pérez-Rodríguez
Gabriela Torres-Mejía
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2018
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-018-1017-8

Other articles of this Issue 1/2018

Breast Cancer Research 1/2018 Go to the issue

Research article

Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis

Research article

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Research article

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Research article

Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion

Research Article

SNPs related to vitamin D and breast cancer risk: a case-control study

Research article

Membrane associated collagen XIII promotes cancer metastasis and enhances anoikis resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits